Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

76,302

Employees76,302

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

76,302

Employees76,302

NVO Key Statistics

Market cap

259.49B

Market cap259.49B

Price-Earnings ratio

16.45

Price-Earnings ratio16.45

Dividend yield

2.18%

Dividend yield2.18%

Average volume

18.23M

Average volume18.23M

High today

$59.28

High today$59.28

Low today

$57.24

Low today$57.24

Open price

$57.04

Open price$57.04

Volume

870.91K

Volume870.91K

52 Week high

$93.80

52 Week high$93.80

52 Week low

$43.08

52 Week low$43.08

NVO News

TipRanks 12h

Novo Nordisk initiated with an Outperform at CICC

CICC initiated coverage of Novo Nordisk (NVO) with an Outperform rating and $73.50 price target Claim 70% Off TipRanks Premium Published first on TheFly – the...

TipRanks 21h

Novo Nordisk Expands CagriSema Push Into Youth Diabetes: Early Trial Update for Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Novo Nordisk Targets Youth Diabetes With New CagriSema...

TipRanks 21h

Novo Nordisk’s CagriSema Appetite Study Adds Depth to Its Obesity Pipeline

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Novo Nordisk is running a clinical stud...

Analyst ratings

56%

of 34 ratings

Buy

55.9%

Hold

32.4%

Sell

11.8%

More NVO News

Cheddar 2d

Inside Novo Nordisk’s Boldest Move Yet: A Weight-Loss Pill for the Masses

Inside Novo Nordisk’s Boldest Move Yet: A Weight-Loss Pill for the Masses Daniel Gilbert, Business of Medicine Reporter at The Washington Post, breaks down Nov...

Nasdaq 3d

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial?

Key Points Novo Nordisk has released a pill version of its GLP-1 drug. In 2025, the company announced that it was ending a GLP-1 trial related to the drug's i...

Simply Wall St 3d

Is Novo Nordisk Attractive After Recent Share Price Weakness And DCF Upside?

If you are wondering whether Novo Nordisk is attractively priced right now, the key question is whether the current share price reflects its long term prospects...

Decrypt 4d

Novo Nordisk Launches $149 Wegovy Pill, Expanding Access to GLP-1 Weight-Loss Drugs

In brief Novo Nordisk rolled out an oral version of Wegovy in the U.S., marking the first pill-based GLP-1 approved specifically for weight loss. GLP-1 drugs f...

TipRanks 4d

Novo Nordisk’s U.S. public affairs boss exits company, Reuters reports

Novo Nordisk’s (NVO) head of public affairs in the U.S. Jennifer Duck has departed the company, Reuters’ Maggie Fick and Dan Levine report, citing an internal m...

Barron's 4d

Novo Nordisk’s Wegovy Pill Hits Pharmacies. It’s the Latest Move in the Weight-Loss Showdown.

Biotech and Pharma Novo Nordisk’s Wegovy Pill Hits Pharmacies. It’s the Latest Move in the Weight-Loss Showdown. In this article NOVO.B LLY GDRX The Wegovy pill...

MarketWatch 4d

Novo Nordisk’s weight-loss pill is available. Here’s why Lilly’s and Viking’s stocks are down.

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the United States. The pill is...